Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison

Akhil Chopra, Mina Georgieva, Gilberto Lopes, Chong Ming Yeo, Benjamin Haaland

Research output: Contribution to journalArticle

Abstract

BACKGROUND: To perform a comparative effectiveness analyses between enzalutamide and abiraterone acetate in both the pre-docetaxel and post-docetaxel settings based on published phase III randomized trials. METHODS: The primary measure of efficacy was the posterior probability that enzalutamide outperforms abiraterone acetate (AA) with prednisone in terms of overall survival (OS) on average. Indirect meta-estimates were generated from four randomized studies in the context of a Bayesian hierarchical model with study-specific efficacy estimates meta-analyzed on the log scale. RESULTS: We found weak evidence that enzalutamide outperforms AA with prednisone in terms of OS in the pre-docetaxel and post-docetaxel settings. However, we found strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS, time until PSA progression, and PSA response rate in both the pre- and post-docetaxel settings. Rates of grade 3 or worse adverse events were broadly similar between treatment (enzalutamide or AA) and control arms (placebo or placebo with prednisone) in all included randomized studies. CONCLUSIONS: There is strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS and PSA progression and PSA response rate but not OS in the pre and post-docetaxel settings. These results may further guide clinicians in making treatment recommendations for patients with advanced prostate cancer. Prostate 77: 639–646, 2017.

LanguageEnglish (US)
Pages639-646
Number of pages8
JournalProstate
Volume77
Issue number6
DOIs
StatePublished - May 1 2017
Externally publishedYes

Fingerprint

docetaxel
Castration
Prostatic Neoplasms
Prednisone
Survival
Placebos
MDV 3100
abiraterone
Abiraterone Acetate
Prostate

Keywords

  • abiraterone
  • advanced prostate cancer
  • castrate-resistant
  • enzalutamide

ASJC Scopus subject areas

  • Oncology
  • Urology

Cite this

Chopra, A., Georgieva, M., Lopes, G., Yeo, C. M., & Haaland, B. (2017). Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison. Prostate, 77(6), 639-646. DOI: 10.1002/pros.23309

Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer : An Indirect Comparison. / Chopra, Akhil; Georgieva, Mina; Lopes, Gilberto; Yeo, Chong Ming; Haaland, Benjamin.

In: Prostate, Vol. 77, No. 6, 01.05.2017, p. 639-646.

Research output: Contribution to journalArticle

Chopra, A, Georgieva, M, Lopes, G, Yeo, CM & Haaland, B 2017, 'Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison' Prostate, vol. 77, no. 6, pp. 639-646. DOI: 10.1002/pros.23309
Chopra A, Georgieva M, Lopes G, Yeo CM, Haaland B. Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison. Prostate. 2017 May 1;77(6):639-646. Available from, DOI: 10.1002/pros.23309
Chopra, Akhil ; Georgieva, Mina ; Lopes, Gilberto ; Yeo, Chong Ming ; Haaland, Benjamin. / Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer : An Indirect Comparison. In: Prostate. 2017 ; Vol. 77, No. 6. pp. 639-646
@article{8ce8e4570ec6480ea238c3c083fc1cd2,
title = "Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer: An Indirect Comparison",
abstract = "BACKGROUND: To perform a comparative effectiveness analyses between enzalutamide and abiraterone acetate in both the pre-docetaxel and post-docetaxel settings based on published phase III randomized trials. METHODS: The primary measure of efficacy was the posterior probability that enzalutamide outperforms abiraterone acetate (AA) with prednisone in terms of overall survival (OS) on average. Indirect meta-estimates were generated from four randomized studies in the context of a Bayesian hierarchical model with study-specific efficacy estimates meta-analyzed on the log scale. RESULTS: We found weak evidence that enzalutamide outperforms AA with prednisone in terms of OS in the pre-docetaxel and post-docetaxel settings. However, we found strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS, time until PSA progression, and PSA response rate in both the pre- and post-docetaxel settings. Rates of grade 3 or worse adverse events were broadly similar between treatment (enzalutamide or AA) and control arms (placebo or placebo with prednisone) in all included randomized studies. CONCLUSIONS: There is strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS and PSA progression and PSA response rate but not OS in the pre and post-docetaxel settings. These results may further guide clinicians in making treatment recommendations for patients with advanced prostate cancer. Prostate 77: 639–646, 2017.",
keywords = "abiraterone, advanced prostate cancer, castrate-resistant, enzalutamide",
author = "Akhil Chopra and Mina Georgieva and Gilberto Lopes and Yeo, {Chong Ming} and Benjamin Haaland",
year = "2017",
month = "5",
day = "1",
doi = "10.1002/pros.23309",
language = "English (US)",
volume = "77",
pages = "639--646",
journal = "Prostate",
issn = "0270-4137",
publisher = "Wiley-Liss Inc.",
number = "6",

}

TY - JOUR

T1 - Abiraterone or Enzalutamide in Advanced Castration-Resistant Prostate Cancer

T2 - Prostate

AU - Chopra,Akhil

AU - Georgieva,Mina

AU - Lopes,Gilberto

AU - Yeo,Chong Ming

AU - Haaland,Benjamin

PY - 2017/5/1

Y1 - 2017/5/1

N2 - BACKGROUND: To perform a comparative effectiveness analyses between enzalutamide and abiraterone acetate in both the pre-docetaxel and post-docetaxel settings based on published phase III randomized trials. METHODS: The primary measure of efficacy was the posterior probability that enzalutamide outperforms abiraterone acetate (AA) with prednisone in terms of overall survival (OS) on average. Indirect meta-estimates were generated from four randomized studies in the context of a Bayesian hierarchical model with study-specific efficacy estimates meta-analyzed on the log scale. RESULTS: We found weak evidence that enzalutamide outperforms AA with prednisone in terms of OS in the pre-docetaxel and post-docetaxel settings. However, we found strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS, time until PSA progression, and PSA response rate in both the pre- and post-docetaxel settings. Rates of grade 3 or worse adverse events were broadly similar between treatment (enzalutamide or AA) and control arms (placebo or placebo with prednisone) in all included randomized studies. CONCLUSIONS: There is strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS and PSA progression and PSA response rate but not OS in the pre and post-docetaxel settings. These results may further guide clinicians in making treatment recommendations for patients with advanced prostate cancer. Prostate 77: 639–646, 2017.

AB - BACKGROUND: To perform a comparative effectiveness analyses between enzalutamide and abiraterone acetate in both the pre-docetaxel and post-docetaxel settings based on published phase III randomized trials. METHODS: The primary measure of efficacy was the posterior probability that enzalutamide outperforms abiraterone acetate (AA) with prednisone in terms of overall survival (OS) on average. Indirect meta-estimates were generated from four randomized studies in the context of a Bayesian hierarchical model with study-specific efficacy estimates meta-analyzed on the log scale. RESULTS: We found weak evidence that enzalutamide outperforms AA with prednisone in terms of OS in the pre-docetaxel and post-docetaxel settings. However, we found strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS, time until PSA progression, and PSA response rate in both the pre- and post-docetaxel settings. Rates of grade 3 or worse adverse events were broadly similar between treatment (enzalutamide or AA) and control arms (placebo or placebo with prednisone) in all included randomized studies. CONCLUSIONS: There is strong evidence that enzalutamide outperforms AA with prednisone in terms of radiographic PFS and PSA progression and PSA response rate but not OS in the pre and post-docetaxel settings. These results may further guide clinicians in making treatment recommendations for patients with advanced prostate cancer. Prostate 77: 639–646, 2017.

KW - abiraterone

KW - advanced prostate cancer

KW - castrate-resistant

KW - enzalutamide

UR - http://www.scopus.com/inward/record.url?scp=85015436737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85015436737&partnerID=8YFLogxK

U2 - 10.1002/pros.23309

DO - 10.1002/pros.23309

M3 - Article

VL - 77

SP - 639

EP - 646

JO - Prostate

JF - Prostate

SN - 0270-4137

IS - 6

ER -